A randomized trial published in Nature Medicine evaluated whether a polypill-based strategy could improve guideline-directed medical therapy (GDMT) implementation and clinical outcomes in patients with HFrEF. The study randomized 212 adults with LVEF ≤40% to receive either a once-daily polypill containing metoprolol succinate, spironolactone, and empagliflozin or enhanced usual care. Key Findings The polypill group demonstrated greater improvement in left ventricular ejection fraction (LVEF) at 6 months compared with enhanced usual care (40.4% vs. 37.1%; between-group difference: 3.3 percentage points; P=0.039).
Patients receiving the polypill had a 60% lower rate of heart failure hospitalization or emergency department visits (adjusted rate ratio: 0.40; P=0.024). Medication adherence was significantly higher with the polypill strategy compared with enhanced usual care (79% vs. 54%;…
